1391052-61-1: Bendamustine Trihydroxyethyl Dimer Impurity

Bendamustine Trihydroxyethyl compound Impurity ( CAS No: 1391052-61-1 ) or 4-(5-((2-((4-(5-(bis(2-hydroxyethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoyl)oxy)ethyl)(2-hydroxyethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid is associate impurity of Bendamustine. Bendamustine is employed to treat chronic leukemia (CLL; a kind of cancer of the white blood cells). Bendamustine is additionally accustomed to treating a kind of non-Hodgkins malignant neoplastic disease.

Additional information

Catalogue No.

VE007301

CAS No.

1391052-61-1

Molecular Formula

C32H44N6O7

Molecular Weight

624.73 g/mol

IUPAC Name

4-(5-((2-((4-(5-(bis(2-hydroxyethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoyl)oxy)ethyl)(2-hydroxyethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid

Synonyms

Bendamustine Deschloro Dimer Impurity

References

“Sci-Hub, Bendamustine: Rebirth of an Old Drug, 10.1200/Jco.2008.18.7252.” Hkvisa.net, 2022, sci-hub.hkvisa.net/10.1200/jco.2008.18.7252.

Status

In-stock